Friday, 22 August 2025
  
Login

Australia's most trusted
source of pharma news

Friday, 22 August 2025
News

PBS newcomers hit the fast lane

Posted 21 August 2025 AM

After winning reimbursement just last year Pfizer's heart drug Vyndamax has taken off, recording the second highest growth in dollar terms on the PBS in the first half of 2025, beaten only by MSD's oncology juggernaut, Keytruda.

The transthyretin stabiliser was listed in May 2024 for adults with wild-type or hereditary transthyretin amyloid cardiomyopathy with NYHA Class I-II heart failure. It earned Pfizer $84 million more between January and June, than the same period last year.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (14)

Clinical & Medical, R&D (12)

Regulatory, Pharmacovigilance & QA (5)

Devices (1)

Other (15)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.